Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: evidence from cell-free DNA analysis
Background Antibody-mediated rejection (AMR) often progresses to poor health outcomes
in lung transplant recipients (LTRs). This, combined with the relatively insensitive clinical
tools used for its diagnosis (spirometry, histopathology) led us to determine whether clinical
AMR is diagnosed significantly later than its pathologic onset. In this study, we leveraged the
high sensitivity of donor-derived cell-free DNA (ddcfDNA), a novel genomic tool, to detect
early graft injury after lung transplantation. Methods We adjudicated AMR and acute cellular …
in lung transplant recipients (LTRs). This, combined with the relatively insensitive clinical
tools used for its diagnosis (spirometry, histopathology) led us to determine whether clinical
AMR is diagnosed significantly later than its pathologic onset. In this study, we leveraged the
high sensitivity of donor-derived cell-free DNA (ddcfDNA), a novel genomic tool, to detect
early graft injury after lung transplantation. Methods We adjudicated AMR and acute cellular …